GlassScriptPhysician profile
Gregg M Santilli
NPI 1023099082
$89,732.31
in general payments reported to CMS, 2019-2025
42 companies · $17K in 2025
The $17K reported for 2025 was more than what 91% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,203 · 2020: $2,128 · 2021: $3,662 · 2022: $10K · 2023: $6,774 · 2024: $45K · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $53K · Food and Beverage: $13K · Consulting Fee: $2,000 · Education: $208 · Travel and Lodging: $77.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $52,950.00 |
| Food and Beverage | $13,143.77 |
| Consulting Fee | $2,000.00 |
| Education | $207.99 |
| Travel and Lodging | $77.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $63,589.70 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Optinose US, INC. | $7,723.18 | 2019-2025 | |
| Abbvie INC. | $2,864.02 | 2021-2025 | Rinvoq |
| Glaxosmithkline, LLC. | $2,389.40 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Regeneron Healthcare Solutions, INC. | $2,281.97 | 2019-2025 | Dupixent |
| Amgen INC. | $2,257.94 | 2021-2025 | Tezspire |
| Genzyme Corporation | $1,077.41 | 2019-2025 | |
| Grifols USA, LLC | $1,063.59 | 2019-2025 | Xembify, Gamunex-C |
| Novartis Pharmaceuticals Corporation | $923.92 | 2019-2025 | |
| Pfizer INC. | $689.63 | 2020-2025 | |
| Covis Pharma Gmbh | $651.54 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $636.41 | 2020-2025 | Cuvitru, Takhzyro |
| Alk-Abello, INC | $477.70 | 2019-2025 | Odactra, Ragwitek, Grastek |
| Octapharma USA, INC. | $347.31 | 2019-2024 | Cutaquig |
| Leo Pharma INC. | $301.89 | 2022-2024 | Adbry |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $258.60 | 2020-2025 | Xolair |
| Ars Pharmaceuticals Operations, INC. | $228.01 | 2025 | Neffy |
| Incyte Corporation | $197.28 | 2021-2024 | Opzelura |
| Teva Pharmaceuticals USA, INC. | $191.95 | 2020-2022 | |
| Lilly USA, LLC | $173.90 | 2024-2025 | Ebglyss, Taltz |
| Biocryst US Sales Co., LLC | $123.31 | 2021-2024 | Orladeyo |
| Blueprint Medicines Corporation | $121.86 | 2025 | Ayvakit |
| Organon LLC | $110.91 | 2025 | Vtama |
| Shire North American Group INC | $107.91 | 2019 | |
| Azurity Pharmaceuticals, INC. | $102.15 | 2025 | Alvesco |
| Kaleo, INC. | $97.42 | 2020-2023 | Auvi-Q |
| Sanofi-Aventis U.S. LLC | $94.95 | 2023 | |
| Pharming Healthcare, INC. | $91.16 | 2020-2023 | Ruconest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.97 | 2019-2023 | Spiriva Respimat |
| Csl Behring | $88.97 | 2020-2024 | Hizentra, Privigen |
| Aimmune Therapeutics, INC. | $65.34 | 2020-2022 | |
| Mylan Specialty L.P. | $54.22 | 2020-2021 | |
| Phadia US INC. | $46.14 | 2021-2023 | Immunocap |
| Merck Sharp & Dohme LLC | $42.35 | 2021-2023 | |
| Galderma Laboratories, L.P. | $41.58 | 2025 | Nemluvio |
| Dermavant Sciences, INC. | $33.46 | 2024 | Vtama |
| Paratek Pharmaceuticals, INC. | $19.16 | 2025 | Xhance |
| Arcutis Biotherapeutics, INC. | $18.82 | 2025 | Zoryve |
| Regeneron Pharmaceuticals, INC. | $16.64 | 2023 | Dupixent |
| Greer Laboratories, INC. | $16.05 | 2019 | |
| Hikma Pharmaceuticals USA | $12.91 | 2023 | Ryaltris |
| Almirall LLC | $11.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregg Santilli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.